Salmeterol/tiotropium bromide - Boehringer Ingelheim

Drug Profile

Salmeterol/tiotropium bromide - Boehringer Ingelheim

Alternative Names: Tiotropium bromide/salmeterol

Latest Information Update: 20 Nov 2014

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Epoxy compounds; Esters; Ethanolamines; Phenethylamines; Small molecules; Thiophenes; Tropanes
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 20 Nov 2014 Discontinued - Phase-III for Chronic obstructive pulmonary disease in Belgium and Netherlands (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top